Brief: Arcutis Presents Positive Patient-Reported Outcome Data From The Pivotal Arrector Phase 3 Trial In Scalp And Body Psoriasis At European Academy Of Dermatology And Venereology (Eadv) Congress
13/10/2023 13:30
Oct 13 (Reuters) - Arcutis Biotherapeutics Inc ARQT.O :
* ARCUTIS PRESENTS POSITIVE PATIENT-REPORTED OUTCOME DATA
FROM THE
PIVOTAL ARRECTOR PHASE 3 TRIAL IN SCALP AND BODY PSORIASIS AT
EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (EADV) CONGRESS
Source text for Eikon: ID:nGNX14zwF0
Further company coverage: ARQT.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4
Arcutis Q1 product revenue rises 65% yr/yr, net loss narrows
Brief: Arcutis Announces Promotion Of MAS Matsuda To Executive Vice President And Chief Legal Officer To Support Next Phase Of Growth
Brief: Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis
Brief: Arcutis Biotherapeutics Inc Files For Mixed Shelf